Vaccinex, Inc.
VCNX
$0.72
-$0.02-2.70%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 601.00K | 388.00K | 356.00K | 124.00K | 570.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 601.00K | 388.00K | 356.00K | 124.00K | 570.00K |
| Cost of Revenue | 19.79M | 23.82M | 23.82M | 25.01M | 25.44M |
| Gross Profit | -19.19M | -23.43M | -23.47M | -24.88M | -24.87M |
| SG&A Expenses | 6.79M | 6.96M | 7.02M | 6.95M | 6.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.34M | 20.72M | 21.97M | 23.10M | 23.46M |
| Operating Income | -18.74M | -20.34M | -21.62M | -22.97M | -22.89M |
| Income Before Tax | -18.63M | -18.58M | -17.76M | -19.19M | -20.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.63 | -18.58 | -17.76 | -19.19 | -20.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.63M | -18.58M | -17.76M | -19.19M | -20.25M |
| EBIT | -18.74M | -20.34M | -21.62M | -22.97M | -22.89M |
| EBITDA | -18.64M | -20.23M | -21.51M | -22.86M | -22.77M |
| EPS Basic | -9.91 | -12.16 | -24.58 | -46.01 | -63.97 |
| Normalized Basic EPS | -6.19 | -7.60 | -15.36 | -28.76 | -39.98 |
| EPS Diluted | -9.91 | -12.16 | -24.58 | -46.02 | -63.97 |
| Normalized Diluted EPS | -6.19 | -7.60 | -15.36 | -28.76 | -39.98 |
| Average Basic Shares Outstanding | 8.40M | 6.18M | 4.47M | 2.94M | 1.85M |
| Average Diluted Shares Outstanding | 8.40M | 6.18M | 4.47M | 2.94M | 1.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |